Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by AKAMPION

< Previous 1 2 Next >
MetrioPharm Publishes First Trial Data Showing Effects of Host-Directed Therapy in COVID-19
From AKAMPION
Via GlobeNewswire
New investigator-initiated clinical trials of BellaSeno´s resorbable tissue regeneration scaffolds to be conducted in Europe
From AKAMPION
Via GlobeNewswire
selectION, Inc. to Present Update on Clinical Progress at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 11, 2024
From AKAMPION
Via GlobeNewswire
1ST Biotherapeutics, Inc. Announces First Patient Dosed in Phase I/II Study of HPK1 Inhibitor FB849 in Patients with Advanced Solid Tumors
From AKAMPION
Via GlobeNewswire
ImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023
From AKAMPION
Via GlobeNewswire
Thermosome Appoints Dr. Frank Hermann, MD, as Chief Medical Officer and Adds Prof. Alessandro Gronchi, MD, to Clinical Advisory Board
From AKAMPION
Via GlobeNewswire
EBViously Presents Novel In-Vitro Data Demonstrating Potent Infection Prevention of its Vaccine Candidate EBV-001
From AKAMPION
Via GlobeNewswire
Ebenbuild to Receive Public Funding Under UBIC Consortium for Digital Lung Twin Project
From AKAMPION
Via GlobeNewswire
Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6
From AKAMPION
Via GlobeNewswire
Dr. Hartmut Tintrup joins Cellbox Solutions GmbH as new CEO
From AKAMPION
Via GlobeNewswire
BellaSeno Presents Novel Production Workflow for Customized, 3D-Printed Bone Scaffolds
From AKAMPION
Via GlobeNewswire
ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002
From AKAMPION
Via GlobeNewswire
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA
From AKAMPION
Via GlobeNewswire
Dopavision Reports Successful Completion of Enrollment for MyopiaX-1 Trial
From AKAMPION
Via GlobeNewswire
Cellbox Solutions Submits Device Master File (DMF) to the U.S. FDA
From AKAMPION
Via GlobeNewswire
1ST Biotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate FB849 in Combination With KEYTRUDA® (pembrolizumab)
From AKAMPION
Via GlobeNewswire
Thermosome Establishes High-Profile Clinical Advisory Board
From AKAMPION
Via GlobeNewswire
ImmunOs Therapeutics Appoints Dr. Constanze Guenther as Senior Vice President, CMC and Technical Development
From AKAMPION
Via GlobeNewswire
BellaSeno Reports Positive One-Year Patient Follow-Up Data for Resorbable Breast and Pectus Excavatum Scaffolds
From AKAMPION
Via GlobeNewswire
TolerogenixX expands Phase II immune-tolerance trial and closes EUR 12 million Series A financing
From AKAMPION
Via GlobeNewswire
BellaSeno Granted Market Access in Europe for Custom-Made Bone and Pectus Excavatum Scaffolds
From AKAMPION
Via GlobeNewswire
Cellbox Solutions GmbH Awarded €2.5 Million Grant Combined with an Equity Component of up to €10 Million Under the European Innovation Council´s Accelerator Program
From AKAMPION
Via GlobeNewswire
Oliver Healthcare Packaging Strengthens Supply Chain, Adds In-Region Film & Foil Production
From AKAMPION
Via GlobeNewswire
Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Active
From AKAMPION
Via GlobeNewswire
BellaSeno Demonstrates Superior Biomechanical Properties of its 3-D Printed, Resorbable Scaffolds for Bone Reconstruction
From AKAMPION
Via GlobeNewswire
Thermosome Announces Participation in IMAGIO Consortium to Improve Cancer Treatment
From AKAMPION
Via GlobeNewswire
MetrioPharm Receives Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy
From AKAMPION
Via GlobeNewswire
selectION, Inc., Reports Interim Safety and Tolerability Results of Phase 1b Clinical Trial in Atopic Dermatitis
From AKAMPION
Via GlobeNewswire
Thermosome Announces First Patient Dosed in Phase I Trial with Lead Program THE001
From AKAMPION
Via GlobeNewswire
ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002
From AKAMPION
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.